-
As the saying goes, sometimes no decision is a decision, and such was the case in last week's announcement by the Centers for Medicare & Medicaid Services to make no change to its current payment policy for computerized tomography for angiography (CTA).
-
Biophan Technologies; CryoCath Technologies; Edwards Lifesciences; ev3; Naviscan PET Systems; NewCardio; Omron Healthcare; Spectranetics
-
Dr. Rolf Kaese, chief executive of Berlin Heart (Berlin), is resigning from the company, citing strategy differences with Syscore (London), which acquired the company in October 2006.
-
Abbot Laboratories (Abbott Park, Illinois) treceived CE mark approval for a 2.25 mm version of its XIENCE V Everolimus Eluting Coronary Stent System, offering a smaller stent for a wider range of stent sizes for treating a variety of patient types.
-
-
Stem Cell Therapeutics (SCT; Calgary, Alberta) at this year's Stroke meeting reported favorable results from its Beta-hCG + Erythropoietin in Acute Stroke (BETAS) Phase IIa, open label, safety trial conducted at the University of California, Irvine and Hoag Presbyterian Memorial Hospital (Newport Beach, California).
-
A team of researchers at Oregon Health & Science University (OHUSU; Eugene) and Washington University (St. Louis) say they have described for the first time the mechanism that gives a mutant enzyme molecule that they have engineered and patented with potential to become a breakthrough drug for treating heart attacks and strokes.
-
Royal Philips Electronics (Amsterdam, the Netherlands) reported that it will lead a new European Union (EU)-funded research project aimed at improving care of heart patients through the development of telemonitoring solutions. The HeartCycle project, which follows the MyHeart project in the EU, was launched on March 1, and will be one of the largest biomedical and healthcare research projects within the EU, according to Philips.
-
The FDA has placed a large speed bump in front of the plans for a confirmatory clinical trial by Vasogen (Mississauga, Ontario) for its heart failure treatment.
-
Michael Mussallem, CEO and chairman of Edwards Lifesciences, (Irvine, California), has been named chairman of AdvaMed (Washington). He succeeds Edward Ludwing, president/CEO and chairman of BD (Franklin Lakes, New Jersey), who has led the organization for the past two years.
